Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Intangibles (2020 - 2025)

Ascendis Pharma A (ASND) has disclosed Intangibles for 6 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • Quarterly Intangibles changed 0.33% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Dec 2025, changed 0.33% year-over-year, with the annual reading at $4.3 million for FY2025, 0.33% changed from the prior year.
  • Intangibles hit $4.3 million in Q4 2025 for Ascendis Pharma A, roughly flat from $4.3 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $6.5 million in Q4 2021 to a low of $2.3 million in Q4 2022.
  • Historically, Intangibles has averaged $4.0 million across 5 years, with a median of $4.3 million in 2024.
  • Biggest five-year swings in Intangibles: tumbled 65.34% in 2022 and later skyrocketed 74.24% in 2024.
  • Year by year, Intangibles stood at $6.5 million in 2021, then crashed by 65.34% to $2.3 million in 2022, then rose by 8.97% to $2.5 million in 2023, then surged by 74.24% to $4.3 million in 2024, then rose by 0.33% to $4.3 million in 2025.
  • Business Quant data shows Intangibles for ASND at $4.3 million in Q4 2025, $4.3 million in Q4 2024, and $2.5 million in Q4 2023.